JPMorgan Chase & Co. Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price

CVS Health (NYSE:CVS) had its target price lifted by research analysts at JPMorgan Chase & Co. from $111.00 to $118.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the pharmacy operator’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 26.22% from the company’s current price.

CVS has been the topic of several other research reports. Truist Financial lifted their price target on CVS Health from $108.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. UBS Group raised their price objective on shares of CVS Health from $122.00 to $126.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Argus lifted their target price on shares of CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. Royal Bank Of Canada increased their price target on shares of CVS Health from $107.00 to $113.00 and gave the company an “outperform” rating in a research note on Thursday, July 9th. Finally, DA Davidson raised their price target on shares of CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Twenty-two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.75.

CVS Health Price Performance

CVS traded down $0.01 on Wednesday, reaching $93.49. 449,127 shares of the company’s stock were exchanged, compared to its average volume of 8,436,496. CVS Health has a twelve month low of $65.26 and a twelve month high of $110.68. The stock has a market cap of $119.57 billion, a PE ratio of 24.78, a P/E/G ratio of 0.91 and a beta of 0.61. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The stock’s fifty day moving average price is $102.43 and its 200-day moving average price is $88.00.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. The business had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business’s revenue was up 7.3% on a year-over-year basis. During the same period last year, the company posted $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Sell-side analysts expect that CVS Health will post 8.02 EPS for the current year.

Insider Transactions at CVS Health

In other news, Director Larry Robbins sold 370,462 shares of the stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the sale, the director owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 3,372,000 shares of company stock worth $317,473,598 in the last 90 days. 0.85% of the stock is owned by corporate insiders.

Institutional Trading of CVS Health

Large investors have recently modified their holdings of the stock. Elevation Wealth Partners LLC increased its position in shares of CVS Health by 41.8% during the second quarter. Elevation Wealth Partners LLC now owns 356 shares of the pharmacy operator’s stock valued at $37,000 after buying an additional 105 shares during the period. Apella Capital LLC boosted its position in CVS Health by 1.7% during the 2nd quarter. Apella Capital LLC now owns 6,940 shares of the pharmacy operator’s stock valued at $724,000 after acquiring an additional 117 shares in the last quarter. CYBER HORNET ETFs LLC grew its holdings in shares of CVS Health by 4.1% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after acquiring an additional 134 shares during the period. LS Investment Advisors LLC grew its holdings in shares of CVS Health by 3.9% during the 4th quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock worth $284,000 after acquiring an additional 135 shares during the period. Finally, Moss Adams Wealth Advisors LLC raised its position in shares of CVS Health by 4.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 3,016 shares of the pharmacy operator’s stock worth $239,000 after acquiring an additional 135 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.